GlassScriptPhysician profile
Andrew Lake
NPI 1821224809
$8,668.74
in general payments reported to CMS, 2019-2025
41 companies · $1,570 in 2025
The $1,570 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $552 · 2021: $1,386 · 2022: $1,164 · 2023: $1,622 · 2024: $1,482 · 2025: $1,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,659 · Education: $14.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,659.18 |
| Education | $14.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,920.07 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $998.51 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $687.21 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $519.18 | 2019-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $502.69 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $440.41 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $348.17 | 2022-2025 | Dupixent |
| Genzyme Corporation | $340.45 | 2022-2025 | |
| Pfizer INC. | $262.27 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $208.03 | 2019-2024 | Dificid |
| Madrigal Pharmaceuticals | $206.46 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $195.79 | 2023-2025 | Ibsrela |
| Daiichi Sankyo INC. | $191.62 | 2019-2024 | Injectafer |
| Medtronic, INC. | $182.19 | 2021-2025 | Interstim, Endoflip, Barrx |
| Qol Medical, LLC | $162.08 | 2021-2023 | Sucraid |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $149.26 | 2024-2025 | Omvoh, Zepbound |
| Celgene Corporation | $143.61 | 2022-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $135.82 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $117.96 | 2024-2025 | Iqirvo, Bylvay |
| Ironwood Pharmaceuticals, INC | $104.70 | 2019-2023 | Linzess |
| Ferring Pharmaceuticals INC. | $97.26 | 2020-2024 | Rebyota |
| Amgen INC. | $90.13 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $67.04 | 2021 | |
| Organon LLC | $67.02 | 2022-2024 | Hadlima, Renflexis |
| Celltrion USA INC. | $65.50 | 2024-2025 | Vegzelma, Zymfentra |
| Olympus America INC. | $63.75 | 2019-2023 | Evis Eus Endoscopic Ultrasound Center, Evis Exera III Duodenovideoscope |
| Boston Scientific Corporation | $58.76 | 2024-2025 | Watchman Flx, Captivator II |
| Ucb, INC. | $49.39 | 2019 | |
| Fresenius Kabi USA, LLC | $48.64 | 2023-2024 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $33.20 | 2022 | |
| Aimmune Therapeutics, INC. | $32.04 | 2024 | |
| Janssen Scientific Affairs, LLC | $32.03 | 2023 | Stelara |
| Mauna Kea Technologies, INC. | $27.66 | 2023 | |
| Biocon Biologics INC | $18.47 | 2025 | Yesintek |
| Braintree Laboratories, INC. | $16.95 | 2024 | Suflave, Sutab |
| Vivus LLC | $16.43 | 2021 | |
| Pentax of America, INC. | $15.54 | 2022 | |
| Merit Medical Systems INC | $14.91 | 2022 | |
| Evoke Pharma, INC. | $13.41 | 2022 | |
| Alfasigma USA, INC. | $13.27 | 2020 | |
| Intra-Sana Laboratories | $10.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Lake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.